Sofia SIEST
LISTE DES PUBLICATIONS1986-2017
UMR INSERM U1122; IGE-PCV
Directeur Sofia SIEST (Sophie Visvikis-Siest)
Email:
Tél: 00 33 (0)6 07 60 25 69
Université de Lorraine▪ Faculté de Pharmacie ▪
22-30, rue Lionnois ▪ 54000 Nancy ▪ France
______
1/ PUBLICATIONS ORIGINALES DANS DES REVUES A COMITE DE LECTURE
86-1Dumon MF, Visvikis S, Manabe T, Clerc M. Immunochemical study of the plasma low and density lipoproteins in Tangier disease.FEBS Lett. 1986 May 26; 201(1): 163-7. Facteur d’Impact: 3.538
87-1Boerwinkle E, Visvikis S, Welsh D, Steinmetz J, Hanash SM, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man. II. The role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am J Med Genet. 1987 Jul; 27(3): 567-82. Facteur d’Impact: 6.365
87-2Manabe T, Visvikis S, Dumon MF, Clerc M, Siest G. Evaluation of lipoproteins and apolipoproteins in serum of a Tangier patient by micro-scale two-dimensional electrophoresis. Clin Chem. 1987 Apr; 33 (4): 468-72. Facteur d’Impact: 7.905
87-3Manabe T, Visvikis S, Steinmetz J, Galteau MM, Okuyama T, Siest G. Systematic analysis of serum lipoproteins and apolipoproteins by a combined technique of micro two-dimensional electrophoresis. Electrophoresis. 1987;8:325-30. Facteur d’Impact: 3.303
87-4Visvikis S, Dumon MF, Steinmetz J, Manabe T, Galteau MM, Clerc M, et al. Plasma apolipoproteins in Tangier disease, as studied with two-dimensional electrophoresis. Clin Chem. 1987 Jan;33(1):120-2. Facteur d’Impact: 7.905
89-1Choukaife A, Visvikis S, Steinmetz J, Galteau MM, Kabbaj O, Ferard G, et al. Two-dimensional electrophoresis of plasma proteins and high density lipoproteins during inflammation. Electrophoresis. 1989 Nov;10(11):781-4. Facteur d’Impact: 3.303
89-2Gueguen R, Visvikis S, Steinmetz J, Siest G, Boerwinkle E. An analysis of genotype effects and their interactions by using the apolipoprotein E polymorphism and longitudinal data. Am J Hum Genet. 1989 Nov;45(5):793-802. Facteur d’Impact: 10.603
90-1Boerwinkle E, Visvikis S, Chan L. Two polymorphisms for amino acid substitutions in the APOA4 gene. Nucleic Acids Res. 1990 Aug 25;18(16):4966. :Facteur d’Impact: 8.026
90-2De Temmerman P, Visvikis S, Boerwinkle E, Siest G. Study of the sequence tagged site (STS) in the beginning of human apo A4 gene region. Nucleic Acids Res. 1990 Sep 25;18(18):5576. Facteur d’Impact: 8.026
90-3Saile R, Kabbaj O, Visvikis S, Steinmetz J, Steinmetz A, Ferard G, et al. Variations in apolipoproteins serum amyloid A, A-I, A-II, and C-III in severely head-injured patients. J Clin Chem Clin Biochem. 1990 Aug;28(8):519-25. Facteur d’Impact: 7.905
90-4Steinmetz J, Choukaife A, Visvikis S, Henny J, Siest G. Biological factors affecting concentrations of serum LpAI lipoprotein particles in serum, and determination of reference limits. Clin Chem. 1990 Apr;36(4):677-80. Facteur d’Impact: 7.905
90-5Tiret L, Steinmetz J, Herbeth B, Visvikis S, Rakotovao R, Ducimetiere P, et al. Familial resemblance of plasma apolipoprotein B: the Nancy study. Genet Epidemiol. 1990;7(3):187-97. Facteur d’Impact: 3.441
90-6Visvikis S, Chan L, Siest G, Drouin P, Boerwinkle E. An insertion deletion polymorphism in the signal peptide of the human apolipoprotein B gene. Hum Genet. 1990 Mar;84(4):373-5. Facteur d’Impact: 5.069
90-7Visvikis S, Steinmetz J, Boerwinkle E, Gueguen R, Galteau MM, Siest G. Frequency and effects of the apolipoprotein A-IV polymorphism. Clin Genet. 1990 Jun;37(6):435-41. Facteur d’Impact: 3.128
91-1Boerwinkle E, Chen SH, Visvikis S, Hanis CL, Siest G, Chan L. Signal peptide-length variation in human apolipoprotein B gene. Molecular characteristics and association with plasma glucose levels. Diabetes. 1991 Nov;40(11):1539-44. Facteur d’Impact: 8.286
92-1Steinmetz J, Boerwinkle E, Gueguen R, Visvikis S, Henny J,Siest G. Multivariate genetic analysis of high density lipoprotein particles. Atherosclerosis. 1992 Feb;92(2-3):219-27. Facteur d’Impact: 3.794
92-2Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992 Jul;51(1):197-205. Facteur d’Impact: 10.603
92-3Zaiou M, Visvikis S, Visvikis A, Siest G. A rapid and reliable method for direct genotyping of codon 360 in the human apolipoprotein A-IV gene. J Lipid Res. 1992 Jul;33(7):1061-6. Facteur d’Impact: 5.559
93-1Lucotte G, David F, Visvikis S, Leininger-Muller B, Siest G, Babron MC, et al. Apolipoprotein E-epsilon 4 allele and Alzheimer's disease. Lancet. 1993 Nov 20;342(8882):1309. Facteur d’Impact: 38.278
93-2Visvikis S, Cambou JP, Arveiler D, Evans AE, Parra HJ, Aguillon D, et al. Apolipoprotein B signal peptide polymorphism in patients with myocardial infarction and controls. "The ECTIM study". Hum Genet. 1993 Jan;90(5):561-5. Facteur d’Impact: 5.069
94-1Hallman DM, Visvikis S, Steinmetz J, Boerwinkle E. The effect of variation in the apolipoprotein B gene on plasmid lipid and apolipoprotein B levels. I. A likelihood-based approach to cladistic analysis. Ann Hum Genet. 1994 Jan;58(Pt 1):35-64. Facteur d’Impact: 5.069
94-2Lucotte G, Visvikis S, Leininger-Muler B, David F, Berriche S, Reveilleau S, et al. Association of apolipoprotein E allele epsilon 4 with late-onset sporadic Alzheimer's disease. Am J Med Genet. 1994 Sep 15;54(3):286-8. Facteur d’Impact: 6.365
94-3Zaiou M, Visvikis S, Gueguen R, Parra HJ, Fruchart JC, Siest G. DNA polymorphisms of human apolipoprotein A-IV gene: frequency and effects on lipid, lipoprotein and apolipoprotein levels in a French population. Clin Genet. 1994 Sep;46(3):248-54. Facteur d’Impact: 3.128
94-4Zaiou M, Visvikis S, Gueguen R, Steinmetz J, Parra HJ, Fruchart JC, Siest G . Sources of variability of human plasma apolipoprotein A-IV levels and relationships with lipid metabolism. Genet Epidemiol. 1994;11(2):101-14. Facteur d’Impact: 3.441
95-1Regis-Bailly A, Fournier B, Steinmetz J, Gueguen R, Siest G, Visvikis S. Apo B signal peptide insertion/deletion polymorphism is involved in postprandial lipoparticles' responses. Atherosclerosis. 1995 Nov;118(1):23-34. Facteur d’Impact: 3.794
95-2Siest G, Henny J, Galteau MM, Schiele F, Steinmetz J, Visvikis S. Lipid and lipoprotein genetic variability: an important contribution from the French health examination centers. Clin Biochem. 1995 Feb;28(1):31-8. Facteur d’Impact: 2.076
95-3Soubrier F, Fery I, Verdy E, Rene MN, Varsat B, Visvikis S , Siest G . The frequency of the factor V gene R506Q mutation varies between regions of France. Nouv Rev Fr Hematol. 1995;37(2):175.
95-4Turner PR, Talmud PJ, Visvikis S, Ehnholm C, Tiret L. DNA polymorphisms of the apoprotein B gene are associated with altered plasma lipoprotein concentrations but not with perceived risk of cardiovascular disease: European Atherosclerosis Research Study. Atherosclerosis. 1995 Aug;116(2):221-34. Facteur d’Impact: 3.794
96-1Bohnet K, Pillot T, Visvikis S, Sabolovic N, Siest G. Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. J Lipid Res. 1996 Jun;37(6):1316-24. Facteur d’Impact: 5.559
96-2Bohnet K, Regis-Bailly A, Vincent-Viry M, Schlenck A, Gueguen R, Siest G, Visvikis S. Apolipoprotein E genotype epsilon 4/epsilon 2 in the STANISLAS Cohort Study--dominance of the epsilon 2 allele? Ann Hum Genet. 1996 Nov;60(Pt 6):509-16. Facteur d’Impact: 3.491
96-3Georges JL, Regis-Bailly A, Salah D, Rakotovao R, Siest G, Visvikis S, et al. Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels. Genet Epidemiol. 1996;13(2):179-92. Facteur d’Impact: 3.441
96-4Regis-Bailly A, Visvikis S, Steinmetz J, Feldmann L, Briancon S, Danchin N, et al. Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. Clin Genet. 1996 Nov;50(5):339-47. Facteur d’Impact: 3.128
96-5Regis-Bailly A, Visvikis S, Steinmetz J, Fournier B, Gueguen R, Siest G. Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal. Clin Chim Acta. 1996 Sep 30;253(1-2):127-43. Facteur d’Impact: 2.535
96-6Schlenck A, Visvikis S, O'Kane M, Siest G. High-resolution separation of PCR product and gene diagnosis by Capillary gel electrophoresis. Biomed Chromatogr. 1996 Jan-Feb;10(1):48-50. Facteur d’Impact: 1.966
96-7Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet. 1996 Jun;58(6):1268-78. :Facteur d’Impact: 10.603
97-1Blain H, Jeandel C, Merched A, Visvikis S, Siest G. Apolipoprotein E level in cerebrospinal fluid increases with aging. J Am Geriatr Soc. 1997 Dec;45(12):1536. Facteur d’Impact: 3.737
97-2Merched A, Blain H, Visvikis S, Herbeth B, Jeandel C, Siest G. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J Neurol Sci. 1997 Jan;145(1):33-9. Facteur d’Impact: 2.353
97-3Salah D, Bohnet K, Gueguen R, Siest G, Visvikis S. Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. J Lipid Res. 1997 May;38(5):904-12. Facteur d’Impact: 5.559
97-4Schlenck A, Bohnet K, Aguillon D, Lafaurie C, Siest G,Visvikis S. High sensitivity of laser-induced fluorescence detection in capillary gel electrophoresis for accurate apolipoprotein E genotyping. Biotechniques. 1997 Apr;22(4):736-42. Facteur d’Impact: 2.669
98-1Blain H, Merched A, Visvikis S, Herbeth B, Siest G, Jeandel C. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimert's disease. Alzheimert's report. 1998;1(2):89-94. Facteur d’Impact: 6.373
98-2Cheng S, Pallaud C, Grow MA, Scharf SJ, Erlich HA, Klitz W,Visvikis S, Chen JJ, Pullinger CR, Malloy MJ, Siest G, Kane JP. A multilocus genotyping assay for cardiovascular disease. Clin Chem Lab Med. 1998 Aug;36(8):561-6. Facteur d’Impact: 2.150
98-3Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):84-91. Facteur d’Impact: 6.37
98-4Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett. 1998 Mar 27;425(2):225-8. Facteur d’Impact: 3.538
98-5Merched A, Xia Y, Papadopoulou A, Siest G, Visvikis S. Apolipoprotein AIV codon 360 mutation increases with human aging and is not associated with Alzheimer's disease. Neurosci Lett. 1998 Feb 13;242(2):117-9. Facteur d’Impact: 2.105
98-6Sass C, Herbeth B, Chapet O, Siest G, Visvikis S, Zannad F. Intima-media thickness and diameter of carotid and femoral arteries in children, adolescents and adults from the Stanislas cohort: effect of age, sex, anthropometry and blood pressure. J Hypertens. 1998 Nov;16(11):1593-602. Facteur d’Impact: 4.021
98-7Sass C, Zannad F, Herbeth B, Salah D, Chapet O, Siest G, Visvikis S. Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis. 1998 Sep;140(1):89-95. Facteur d’Impact: 3.794
98-8Shen X, Xia Y, Sass C, Visvikis S, Siest G. Association of apolipoprotein E polymorphism and concentration with serum lipids and apolipoprotein level in the Chinese from Shanghai. Clin Chem Lab Med. 1998 Aug;36(8):615-9. Facteur d’Impact: 2.150
98-9Terrisse L, Poirier J, Bertrand P, Merched A, Visvikis S, Siest G,Milne, R Rassart E. Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients. J Neurochem. 1998 Oct;71(4):1643-50. Facteur d’Impact: 4.061
98-10Vincent-Viry M, Schiele F, Gueguen R, Bohnet K, Visvikis S, Siest G. Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study. Clin Chem. 1998 May;44(5):957-65. Facteur d’Impact: 7.905
98-11Zannad F, Visvikis S, Gueguen R, Sass C, Chapet O, Herbeth B, Siest G . Genetics strongly determines the wall thickness of the left and right carotid arteries. Hum Genet. 1998 Aug;103(2):183-8. Facteur d’Impact: 5.069
98-12Visvikis S, Schlenck A, Maurice M. DNA extraction and stability for epidemiological studies. Clin Chem Lab Med. 1998 Aug;36(8):551-5. Facteur d’Impact: 2.150
99-1Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, Chen, JJ, Pullinger, CR, Malloy, MJ, Siest G, Kane, JP. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res. 1999 Oct;9(10):936-49. Facteur d’Impact: 13.608
99-2Dallongeville J, Tiret L, Visvikis S, O'Reilly DS, Saava M, Tsitouris G, et al. Effect of apo E phenotype on plasma postprandial triglyceride levels in young male adults with and without a familial history of myocardial infarction: the EARS II study. European Atherosclerosis Research Study. Atherosclerosis. 1999 Aug;145(2):381-8. Facteur d’Impact: 3.794
99-3De Backer G, De Henauw S, Sans S, Nicaud V, Masana L, Visvikis S, et al. A comparison of lifestyle, genetic, bioclinical and biochemical variables of offspring with and without family histories of premature coronary heart disease: the experience of the European Atherosclerosis Research Studies. J Cardiovasc Risk. 1999 Jun;6(3):183-8. Facteur d’Impact: 1.21
99-4Pallaud C, Maurice M, Cheng S, Grow M, Aguillon D, Sass C, Siest G,Visvikis S. Multilocus approach to cardiovascular risk. Scand J Clin Lab Invest Suppl. 1999;230:168-76. Facteur d’Impact: 1.38
99-5Schlenck A, Herbeth B, Siest G, Visvikis S. Characterization and quantification of serum lipoprotein subfractions by capillary isotachophoresis: relationships with lipid, apolipoprotein, and lipoprotein levels. J Lipid Res. 1999 Nov;40(11):2125-33. Facteur d’Impact: 5.559
99-6Schlenck A, Schiele F, Barbier A, Shuvaev VV, Visvikis S, Siest G. Capillary electrophoretic analysis of recombinant human apolipoprotein E. Calibration mode of a protein reference material. J Chromatogr A. 1999 Aug 20;853(1-2):237-41. Facteur d’Impact: 4.531
99-7Tregouet DA, Ducimetiere P, Bocquet V, Visvikis S, Soubrier F, Tiret L. A parametric copula model for analysis of familial binary data. Am J Hum Genet. 1999 Mar;64(3):886-93. Facteur d’Impact: 10.603
00-1Dergunov AD, Smirnova EA, Merched A, Visvikis S, Siest G, Yakushkin VV, et al. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E. Biochim Biophys Acta. 2000 Feb 24;1484(1):29-40. Facteur d’Impact: 3.88
00-2Dergunov AD, Smirnova EA, Merched A, Visvikis S, Siest G, Yakushkin VV, et al. Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study. Biochim Biophys Acta. 2000 Feb 24;1484(1):14-28. Facteur d’Impact: 3.88
00-3Garner C, Lecomte E, Visvikis S, Abergel E, Lathrop M, Soubrier F. Genetic and environmental influences on left ventricular mass. A family study. Hypertension. 2000 Nov;36(5):740-6. Facteur d’Impact: 6.207
00-4Kafatos A, Moschandreas J, Hatzis C, Vincent-Viry M, Schiele F, Visvikis S. Apolipoprotein E polymorphisms in Crete and relation to lipoprotein concentrations and other coronary heart disease risk factors. Iatriki. 2000;77(5):452-63.
00-5Merched A, Xia Y, Visvikis S, Serot JM, Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging. 2000 Jan-Feb;21(1):27-30. Facteur d’Impact: 6.189
00-6Sass C,Herbeth B, Siest G, Visvikis S. Lipoprotein lipase (C/G)447 polymorphism and blood pressure in the Stanislas Cohort. J Hypertens. 2000 Dec;18(12):1775-81. Facteur d’Impact: 4.021
00-7Sass C, Pallaud C, Zannad F, Visvikis S. Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas cohort. Hum Genet. 2000 Jul;107(1):58-61. Facteur d’Impact: 5.069
00-8Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A, Kafatos A, Martins MC, Sass C , Visvikis S, De Backer G, Siest G . Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis. 2000 Oct; 152(2):475-88. Facteur d’Impact: 3.794
00-9Siest G, Bertrand P, Qin B, Herbeth B, Serot JM, Masana L, … Visvikis S. Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group. Clin Chem Lab Med. 2000 Aug;38(8):721-30. Facteur d’Impact: 2.150
00-10Xia Y, Sass C, Shen X, Siest G, Visvikis S. Associations of apolipoprotein E concentration and polymorphism with lipids and apolipoprotein levels in Chinese from Beijing and Shanghai. Clin Chem Lab Med. 2000 Jul;38(7):655-9. Facteur d’Impact: 2.150
00-11Visvikis S, Sass C, Pallaud C, Grow MA, Zannad F, Siest G, et al. Familial studies on the genetics of cardiovascular diseases: the Stanislas cohort. Clin Chem Lab Med. 2000 Sep;38(9):827-32. Facteur d’Impact: 2.150
01-1Dergunov AD, Dobretsov GE, Visvikis S, Siest G. Protein-lipid interactions in reconstituted high density lipoproteins: apolipoprotein and cholesterol influence. Chem Phys Lipids. 2001 Nov;113(1-2):67-82. Facteur d’Impact: 2.549
01-2Hoy A, Tregouet D, Leininger-Muller B, Poirier O, Maurice M, Sass C, Siest G, Tiret L, Visvikis S. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet. 2001 Oct; 9(10): 780-6.Facteur d’Impact: 4.400
01-3Mammes O, Aubert R, Betoulle D, Pean F, Herbeth B, Visvikis S, Siest G, Fumeron F. LEPR gene polymorphisms: associations with overweight, fat mass and response to diet in women. Eur J Clin Invest. 2001 May;31(5):398-404. Facteur d’Impact: 3.018
01-4Pallaud C, Gueguen R, Sass C, Grow M, Cheng S, Siest G, Visvikis S, Genetic influences on lipid metabolism trait variability within the Stanislas Cohort. J Lipid Res. 2001 Nov;42(11):1879-90. Facteur d’Impact: 5.559
01-5Pallaud C, Sass C, Zannad F, Siest G,Siest G,Visvikis S. APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas cohort). Clin Genet. 2001 May; 59(5): 316-24. Facteur d’Impact: 3.128
01-6Pallaud C, Sass C, Zannad F, Siest G, Pignatti F, Visvikis S. Candidate gene polymorphisms in cardiovascular disease: a comparative study of frequencies between a French and an Italian population. Clin Chem Lab Med. 2001 Feb; 39(2): 146-54. Facteur d’Impact: 2.150
01-7Serteser M, Visvikis S, Ozben T, Herbeth B, Balkan S, Siest G. Lipid profile and apolipoprotein E genotyping in stroke: a case-control study. Neuroscience-Net.2001; 3:10015.Facteur d’Impact: 0.12
01-8Starck M, Schiele F, Herbeth B, Vincent-Viry M, Beaud B, Siest G, Visvikis S. Apolipoproteins E and C-III in apo B- and non-apo B-containing lipoproteins in middle-aged women from the Stanislas cohort: effect of oral contraceptive use and common apolipoprotein E polymorphism. Atherosclerosis. 2001 Apr;155(2):509-16. Facteur d’Impact: 3.794
01-9Tregouet DA, Aubert H, Henry M, Morange P, Visvikis S, Juhan-Vague I, Tiret L. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet. 2001 Aug; 109(2): 191-7. Facteur d’Impact: 5.069
01-10Tregouet DA, Pallaud C, Sass C, Visvikis S, Tiret L. Sample size calculations for classical association and TDT-type methods using family data. Ann Hum Genet. 2001 May; 65(Pt 3): 293-312. Facteur d’Impact: 2.565
01-11Zannad F, Sass C, Visvikis S. Environmental and genetic determinants of intima-media thickness of the carotid artery. Clin Exp Pharmacol Physiol. 2001 Dec;28(12):1007-10. Facteur d’Impact: 1.85
02-1Ablise M, Cartier A, Siest G, Visvikis S, Loppinet V. Molecular pharmacophore determination of lipid lowering drugs with the receptor mapping method. Mini Rev Med Chem. 2002 Apr; 2(2): 97-102.Facteur d’Impact: 2.53
02-2Brand E, Chatelain N, Paillard F, Tiret L, Visvikis S, Lathrop M, Soubrier F, Demenais F. Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. Eur J Hum Genet. 2002 Nov;10(11):715-23.Facteur d’Impact: 4.400
02-3De Andrade M, Gueguen R, Visvikis S, Sass C, Siest G, Amos CI. Extension of variance components approach to incorporate temporal trends and longitudinal pedigree data analysis.Genet Epidemiol. 2002 Mar;22(3):221-32.Facteur d’Impact: 3.441
02-4Gueguen s, Herbeth B, Pirollet P, Paille F, Siest G, Visvikis S. Changes in serum apolipoprotein and lipoprotein profile after alcohol withdrawal: effect of apolipoprotein E polymorphism. Alcohol Clin Exp Res. 2002 Apr;26(4):501-8. Facteur d’Impact: 3.343
02-5Habdous M, Vincent-Viry M, Visvikis S, Siest G. Rapid spectrophotometric method for serum glutathione S-transferases activity. Clin Chim Acta. 2002 Dec;326(1-2):131-42. Facteur d’Impact: 2.535
02-6Haddy N, De Bacquer D, Chemaly MM, Maurice M, Ehnholm C, Evans A, Sans S, Martins MC, De Backer G, Siest G, Visvikis S. The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. Eur J Hum Genet. 2002 Dec;10(12):841-50. Facteur d’Impact: 4.400
02-7Laffont I, Takahashi M, Shibukawa Y, Honke K, Shuvaev VV, Siest G, Visvikis S, Tanuguchi N. Apolipoprotein E activates Akt pathway in neuro-2a in an isoform-specific manner. Biochem Biophys Res Commun. 2002 Mar 22;292(1):83-7. Facteur d’Impact: 2.484
02-8Schiele F, Vincent-Viry M, Starck M, Beaud B, Hennache G, Siest G, Visvikis S, Herbeth B. Apolipoprotein E in apolipoprotein B (apo B)- and non-apo B-containing lipoproteins in 3523 participants in the Stanislas cohort: biological variation and genotype-specific reference limits. Clin Chem. 2002 Feb; 48(2): 291-300. Facteur d’Impact: 7.905
02-9Soubrier F, Martin S, Alonso A, Visvikis S, Tiret L, Matsuda F, Lathrop M, Farrall M. High-resolution genetic mapping of the ACE-linked QTL influencing circulating ACE activity. Eur J Hum Genet. 2002 Sep; 10(9): 553-61. Facteur d’Impact: 4.400
03-1Dergunov AD, Hoy A, Smirnova EA, Visvikis S, Siest G. Charge-based heterogeneity of human plasma lipoproteins at hypertriglyceridemia: capillary isotachophoresis study. Int J Biochem Cell Biol. 2003 Apr; 35(4): 530-43.Facteur d’Impact: 4.634
03-2Dergunov AD, Perova NV, Visvikis S, Siest G. Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype. Vascul Pharmacol. 2003 Dec; 40(5): 237-45.Facteur d’Impact: 1.986
03-3Dergunov AD, Vorotnikova YY, Visvikis S, Siest G. Homo- and hetero-complexes of exchangeable apolipoproteins in solution and in lipid-bound form. Spectrochim Acta A Mol Biomol Spectrosc. 2003 Mar 15; 59(5): 1127-37. Facteur d’Impact: 2.098
03-4Gueguen s, Pirollet P, Leroy P, Guilland JC, Arnaud J, Paille F, Siest G, Visvikis S, Hercberg S, Herbeth B. Changes in serum retinol, alpha-tocopherol, vitamin C, carotenoids, xinc and selenium after micronutrient supplementation during alcohol rehabilitation. J Am Coll Nutr. 2003 Aug;22(4):303-10.Facteur d’Impact: 2.290
03-5Habdous M, Herbeth B, Vincent-Viry M, Lamont JV, Fitzgerald PS, Visvikis S, Siest G. Serum total antioxidant status, erythrocyte superoxide dismutase and whole-blood glutathione peroxidase activities in the Stanislas cohort: influencing factors and reference intervals. Clin Chem Lab Med. 2003 Feb;41(2):209-15. Facteur d’Impact: 2.150